Upsher-Smith

Upsher-Smith is a century-old, trusted U.S. pharmaceutical company operating as a commercial-stage entity with a hybrid portfolio of branded and generic drugs. Following its acquisition by Bora Pharmaceuticals in April 2024 and subsequent merger with TWi Pharmaceuticals, it has strengthened its pipeline and expanded its product offerings, particularly in neurology and rare diseases. The company's strategy focuses on strategic acquisitions, partnerships, and a commitment to reliable supply to serve patients with cost-effective therapies.

Integrated pharmaceutical development and manufacturing for small molecules, with capabilities across multiple dosage forms, enhanced by R&D expertise from TWi Pharmaceuticals for complex generics and specialty formulations.

Upsher-Smith competes in the crowded generic pharmaceuticals market against large global generics manufacturers like Teva, Viatris, and Sun Pharma. In its targeted specialty neurology and rare disease segments, it faces competition from both large biopharma companies and specialized biotechs with greater R&D budgets and established commercial infrastructures.